Meeting
2023 ASCO Annual Meeting
De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
Authors
Nyelia Williams
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH
Nyelia Williams , Caroline E. Wheeler , Marium Husain , Rebecca Hoyd , Alexa Simon Meara , Mari Lynn , Amna Bibi , Bailey Conrad , Shannon Gray , Michael Bodnar , Namrata Arya , Scott Roberts , Phuong Hoang , Jessica Apparicio , Deanna Merrill , Richard Cheng Han Wu , Claire F. Verschraegen , Christin Elizabeth Burd , Kari Lynn Kendra , Daniel Spakowicz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT05102773
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9569)
DOI
10.1200/JCO.2023.41.16_suppl.9569
Abstract #
9569
Poster Bd #
332
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
First Author: Nyelia Williams
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2023 ASCO Annual Meeting
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
First Author: Piyush Grover
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).
First Author: Hewitt Chang